癌症研究
阿霉素
血小板
癌细胞
药品
基质金属蛋白酶
药理学
肿瘤微环境
化学
凝血酶
癌症
化疗
医学
生物化学
免疫学
肿瘤细胞
内科学
作者
Yue Ke,Zhifang Ma,Hongbo Ye,Xinghua Guan,Zehong Xiang,Yu Xia,Qiang Shi
标识
DOI:10.1002/adhm.202202205
摘要
Abstract Hypercoagulation threatens the lives of cancer patients and cancer progression. Platelet overactivation attributes to the tumor‐associated hypercoagulation and maintenance of the tumor endothelial integrity, leading to limited intratumoral perfusion of nanoagents into solid tumors in spite of the enhanced penetration and retention effect (EPR). Therefore, the clinical application of nanotherapeutics in solid cancer still faces great challenges. Herein, this work establishes platelet inhibiting nanoagents based on Fe III ‐doped C 3 N 4 coloaded with the chemotherapy drug and the antiplatelet drug chlorogenic acid (CA), further opening tumor vascular endothelial junctions, thereby disrupting the tumor vascular endothelial integrity, and enhancing drug perfusion. Moreover, CA not only damages the cancer cells but also potentiates the cytotoxicity induced by the chemotherapy drug doxorubicin, synergistically ablating the tumor tissue. Further, the introduction of CA relieves the original causes of the hypercoagulable state such as tissue factor (TF), thrombin, and matrix metalloproteinases (MMPs) secreted by cancer cells. It is anticipated that the hypercoagulation‐ and platelet‐inhibition strategy by integration of phenolic acid CA into chemotherapy provides insights into platelet inhibition‐assisted theranostics based on nanomedicines.
科研通智能强力驱动
Strongly Powered by AbleSci AI